Humacyte Submits Supplemental Biologics License Application to FDA for the Acellular Tissue Engineered Vessel in Dialysis Access
Humacyte has submitted a supplemental Biologics License Application (sBLA) to the FDA for its acellular tissue engineered vessel (ATEV) to be approved for arteriovenous (AV) access in hemodialysis patients, particularly those at increased risk of AV fistula maturation failure. This application is supported by positive results from three Phase 3 studies, including the V012 trial which showed the ATEV outperformed AV fistulas in women. If approved, the ATEV would offer a new, potentially safer and more reliable option for the nearly 500,000 Americans dependent on hemodialysis.
Humacyte reports ATEV shows low atherosclerosis risk in long term results
Humacyte presented new long-term clinical data for its ATEV vessel at the 2026 ISVTE-ISACB Joint Meeting. The analysis, covering ATEVs from 52 patients across five clinical trials, showed a low susceptibility to atherosclerosis over time. This follows earlier interim Phase 3 results for ATEV in women requiring hemodialysis access and previous presentations on bioengineered human vessels.
Five Presentations, One Leading Innovation: Humacyte’s Acellular Tissue Engineered Vessel Takes Center Stage at VEITH 2026
Humacyte, Inc. announced that its acellular tissue engineered vessel (ATEV), Symvess, will be featured in five presentations at the 53rd Annual VEITHsymposium. The presentations will cover various aspects of ATEV use, including vascular reconstruction in infected fields, interim Phase 3 results in women receiving hemodialysis, integrated durability and safety outcomes, histologic evidence from explanted vessels, and clinical experience in military and civilian trauma settings. Symvess is approved by the FDA for extremity arterial injury when urgent revascularization is needed and autologous vein graft is not feasible.
Humacyte Inc Lobbying Profile, 2026
This OpenSecrets profile details Humacyte Inc.'s lobbying activities for 2026, categorizing it under the Pharmaceuticals/Health Products industry. As of July 23, 2026, the company has spent $150,000 directly on federal lobbying. The page provides an overview of their spending, hired firms, lobbyists, issues, agencies targeted, and relevant bills.
Humacyte to present new clinical data on bioengineered vascular grafts at VEITHsymposium
Humacyte announced it will present new data on its acellular tissue engineered vessels at the VEITHsymposium on November 18. This presentation, led by Dr. Rishi Kundi, will focus on the clinical applications of these bioengineered human vessels for patient care. The company has also recently reported increased demand for its Symvess products and positive interim Phase 3 results for hemodialysis access in women.
StoneX reiterates Humacyte stock rating on strong sales growth
StoneX reiterated a Speculative Buy rating and $1.00 price target on Humacyte (NASDAQ:HUMA) after the company reported strong third-quarter results, exceeding revenue consensus. The company saw its stock surge and significant growth in Symvess sales, which are expected to double in the fourth quarter, reaching 49 hospitals. Despite a current market cap of $165 million, InvestingPro analysis indicates the stock is undervalued at its $0.60 price.
Humacyte Q3 2026 Deep Dive: EPS Beats, Revenue Up 36%
Humacyte reported a Q3 2026 earnings beat, with a loss of $0.06 per share against an expected $0.09, and revenue up 36.5% year-over-year to $1.0 million, driven by strong sequential growth in its Symvess vascular graft product. While the company remains unprofitable with negative gross margins, the significant acceleration in commercial adoption suggests potential market penetration. Investors are closely watching for sustained hospital adoption and improvements in manufacturing scale to achieve positive gross margins, which are critical for future profitability.
With $64.5M in cash, Humacyte (HUMA) warns funding depends on timely sales cash flows or new capital.
Humacyte (HUMA) reported third-quarter 2026 revenue of $1.028 million and a net loss of $15.538 million. The company announced that its $64.5 million in cash and equivalents might not sustain operations beyond one year unless it achieves timely commercial sales cash flows or secures additional capital, raising substantial doubt about its ability to continue as a going concern. Humacyte anticipates ongoing operating losses and negative operating cash flows.
Humacyte Q3 Earnings Call Highlights
Humacyte reported a significant increase in Q3 Symvess sales, up 151% from the previous quarter, and anticipates a doubling of sales in Q4 as hospital adoption grows. The company also plans to submit an application to the FDA in November to expand the use of its acellular tissue-engineered vessel (ATEV) for dialysis access and has initiated a first-in-human study for its coronary tissue-engineered vessel. These developments, along with narrowed financial losses, position Humacyte for potential value creation.
Humacyte Releases Q3 2026 Financial Results
Humacyte, Inc. announced its Q3 2026 financial results, reporting a narrower-than-expected loss of $0.06 per share, beating analyst estimates. The company's revenue increased by 36.5% year-over-year to $1.0 million, driven by the commercial rollout and gradual uptake of its Symvess vascular graft product in 49 hospitals. Despite a net loss of $15.5 million due to expansion investments, analyst sentiment remains positive with a consensus of 6 buys and 2 holds.
Humacyte Q3 2026 Earnings Call Transcript
Humacyte reported a 151% increase in Synvest sales for Q3 2026, reaching over $1 million, and expects to double sales in Q4. The company is preparing to submit a supplemental Biologics License Application (sBLA) for its ATEV product for dialysis access and has initiated a Phase 2a clinical study for Coronary Tissue Engineered Vessels (CTEV) for coronary artery bypass grafting. Despite a net loss of $15.5 million in Q3 2026, Humacyte saw an improvement from the previous year and is optimistic about future growth driven by its commercial strategy and pipeline progress.
Humacyte Releases Q3 2026 Financial Results
Humacyte, Inc. announced its Q3 2026 financial results, reporting a narrower-than-expected loss of $0.06 per share, surpassing analyst estimates by 33.3%. The company's revenue reached $1.0M, a 36.5% increase year-over-year, driven by the commercial rollout of its Symvess vascular graft product. Humacyte continues to expand the adoption of its bioengineered tissues, with 49 hospitals ordering Symvess during the quarter.
Humacyte Reports Third Quarter 2026 Results, Highlighted by More Than Doubling Symvess Revenue and Expanding Commercial Adoption
Humacyte, Inc. announced strong financial results for the third quarter of 2026, with Symvess revenue more than doubling to $1.0 million, demonstrating accelerating commercial adoption for vascular injury repair. The company also reported progress in its pipeline, including plans to file a supplemental Biologics License Application (sBLA) for its ATEV in dialysis access and the initiation of a Phase 2a study for CTEV in coronary artery bypass grafting (CABG). These developments highlight Humacyte's continued growth and advancement of its bioengineered human tissue platform.
Form 8K Humacyte Inc For: 10 November By Investing.com
This article from Investing.com announces the filing of a Form 8K by Humacyte Inc. on November 10. The filing is a routine disclosure that companies make with the SEC to announce significant events that shareholders should know about. No specific details of the Form 8K content are provided within the article.
Humacyte, Inc. (HUMA) Tops Q3 EPS by 4c
Humacyte, Inc. (HUMA) reported Q3 EPS of ($0.06), which was $0.04 better than the analyst estimate of ($0.10). The company's revenue for the quarter came in at $1.03 million, surpassing the consensus estimate of $769.38 thousand. Following this news, Humacyte's stock price increased by over 26%.
HUMACYTE ($HUMA) Releases Q3 2026 Earnings
HUMACYTE ($HUMA) announced its Q3 2026 earnings, reporting -$0.07 per share, surpassing estimates of -$0.09. The company also beat revenue estimates with $1,030,000. The article details recent insider trading activity, with more purchases than sales, and provides an overview of institutional investor movements and analyst price targets for the stock.
Humacyte, Inc. (HUMA) Registers a Bigger Fall Than the Market: Important Facts to Note
Humacyte, Inc. (HUMA) shares fell by 12.11% in the latest trading session, underperforming the broader S&P 500's 4.36% loss. The company is set to announce its earnings on November 10, 2026, with projected EPS of -$0.09 and revenue of $0.86 million, indicating significant growth from the previous year. Despite recent declines, the stock holds a Zacks Rank of #3 (Hold), and its industry ranks in the top 45% of all industries.
Two talks will cover Humacyte's experimental vessel for heart bypass
Humacyte (Nasdaq: HUMA) will present its regenerative medicine technology, including an experimental coronary tissue engineered vessel for heart bypass, at the American Heart Association Scientific Sessions 2026. Founder and CEO Laura Niklason will give an invited talk on vascular regeneration, while two other presentations will detail the Phase 2a study design and preclinical results for the coronary vessel. The conference will take place in Chicago from November 6-9, 2026, and the coronary vessel remains investigational.
Humacyte To Announce 2026 Third Quarter Financial Results and Provide Business Update on November 10, 2026
Humacyte announced it will release its third-quarter 2026 financial results on November 10, 2026. The company will also provide a business update on the same day. Investors and interested parties can expect to learn about Humacyte's performance and strategic developments during the webcast and conference call.
Humacyte, Inc. (HUMA) stock price, news, quote and history
Humacyte, Inc. (HUMA) stock closed at $0.3981, down 3.19%, with an overnight gain to $0.4115. The biotechnology company, headquartered in Durham, North Carolina, develops off-the-shelf bioengineered human tissues for various medical treatments, including vascular repair and dialysis access. Despite significant year-to-date and annual declines, analysts have an average 1-year target estimate of $1.62.
Humacyte To Announce 2026 Third Quarter Financial Results and Provide Business Update on November 10, 2026
Humacyte, Inc. announced it will release its third quarter and nine-month financial results for 2026 on Tuesday, November 10, 2026. The company will also host a webcast and conference call at 8:00 a.m. Eastern Time to provide a corporate and financial update. Humacyte is a commercial-stage biotechnology platform company focused on developing universally implantable, bioengineered human tissues.
Humacyte To Announce 2026 Third Quarter Financial Results and Provide Business Update on November 10, 2026
Humacyte, Inc. (Nasdaq: HUMA) announced it will release its financial results for the three and nine months ended September 30, 2026, on Tuesday, November 10, 2026. The company will also host a webcast and conference call at 8:00 a.m. Eastern Time on the same day to provide a corporate and financial update. Humacyte is a commercial-stage biotechnology company developing universally implantable, bioengineered human tissues.
Humacyte (HUMA) Stock Price, Chart & Analysis
This article provides a detailed analysis of Humacyte (HUMA) stock, including its current price, market capitalization, key financial figures, and a quality score based on various metrics. It also offers insights into the company's growth, valuation, and an "at a glance" summary of its financial health according to De Belegger's rules of thumb. The analysis concludes with potential future scenarios for the stock's performance.
Humacyte, Inc. (HUMA) Seasonal returns chart
The article provides a seasonal returns chart for Humacyte, Inc. (HUMA), displaying the average monthly price return from 2020 to 2026. It also includes current stock information, showing a closing price of 0.4112 USD with a 12.47% decrease, followed by an overnight gain of 4.26%.
Humacyte, Inc. (HUMA) Suffers a Larger Drop Than the General Market: Key Insights
Humacyte, Inc. (HUMA) shares fell 13.01% in the latest trading session, significantly underperforming the broader S&P 500. Over the past month, the company's stock has decreased by 6.58%, contrasting with gains in the Medical sector and S&P 500. Investors are anticipating Humacyte's upcoming earnings report, with projections for significant EPS and revenue growth year-over-year.
Humacyte, Inc. (HUMA) Suffers a Larger Drop Than the General Market: Key Insights
Humacyte, Inc. (HUMA) experienced a significant -13.01% drop in its latest trading session, underperforming the broader market indices like the S&P 500, Dow, and Nasdaq. Despite recent monthly declines, analysts project a 35.71% EPS growth and 14.67% revenue increase for the upcoming quarter. The company currently holds a Zacks Rank #3 (Hold), placing its industry in the top 42% of over 250 industries.
Humacyte Strengthens Intellectual Property Portfolio with Issuance of New U.S. Patent Covering Symvess and Other Bioengineered Tissues
Humacyte, Inc. announced the issuance of a new U.S. patent, No. 12,742,144, extending protection for key aspects of its bioengineering platform, including the manufacturing, sterilization, storage, and shipping of Symvess® and other bioengineered human tissues, until 2043. This patent strengthens the company's intellectual property and enhances its ability to commercialize next-generation regenerative medicine products. Symvess, Humacyte's lead product, is a bioengineered human tissue intended as a universally implantable vascular conduit, with plans to submit a supplemental BLA for dialysis access following its December 2024 FDA approval for vascular trauma.
Humacyte receives U.S. patent covering Symvess manufacturing process
Humacyte, Inc. announced the issuance of U.S. Patent No. 12,742,144, which covers key aspects of the manufacturing, sterilization, storage, and shipping of its Symvess product and other bioengineered human tissues. This patent extends protection until 2043 and strengthens the company's intellectual property portfolio. Symvess, known as the acellular tissue engineered vessel (ATEV), received FDA approval in December 2024 for extremity vascular trauma and Humacyte plans to seek approval for dialysis access as a second indication.
A new patent protects how a bioengineered blood vessel is made and shipped through 2043.
Humacyte Inc. announced the issuance of a new U.S. patent, No. 12,742,144, extending protection for its Symvess bioengineered blood vessel and other human tissues until 2043. This patent specifically covers key aspects of the manufacturing, sterilization, storage, and shipping processes. The company's lead product, Symvess, received FDA approval for extremity vascular trauma in December 2024, and Humacyte plans to submit a supplemental biologics license application in 2026 for dialysis access as a second indication.
Humacyte, Inc. Estimates – NASDAQ:HUMA
This page provides an overview of Humacyte, Inc.'s financial estimates, including income statement, balance sheet, cash flow, and valuation metrics for both annual and quarterly periods. It allows users to explore reported financial data and analyst estimates, comparing actual results with average, high, and low projections. The platform also visualizes trends over time to assist with financial analysis.
Humacyte, Inc. (HUMAW) Stock Price, News, Quote & History
Humacyte, Inc. (HUMAW) saw a significant stock price drop of 78.05%, closing at $0.0009. The company focuses on developing and manufacturing off-the-shelf, bioengineered human tissues for various medical treatments, including vascular repair and cell therapy delivery. Despite a Q2 FY26 revenue of $406k, Humacyte reported a substantial earnings loss of -$36.8 million, highlighting ongoing financial challenges.
Humacyte at ASN Kidney Week: Phase 3 Trial Built for Women Shows ATEV Advantage Over Fistula, Getting Patients Off Catheters Months Sooner
Humacyte, Inc. announced positive interim results from its V012 Phase 3 clinical trial, showing that its acellular tissue engineered vessel (ATEV) offers significant advantages over arteriovenous (AV) fistula for hemodialysis access in women. Women implanted with the ATEV achieved functional access months sooner and spent more catheter-free days. These findings suggest the ATEV could be a crucial new option for female hemodialysis patients, who often experience poorer outcomes with traditional AV fistulas.
Why Humacyte, Inc. (HUMA) Outpaced the Stock Market Today
Humacyte, Inc. (HUMA) shares increased by 1.28% in the latest session, outperforming the S&P 500, Dow, and Nasdaq. Despite a recent 30.34% loss over the past month, analysts project a 35.71% increase in EPS for the upcoming earnings report and a significant 98.48% rise in annual revenue. The company currently holds a Zacks Rank of #3 (Hold), placing its industry in the top 42% of all industries.
Humacyte, Inc. (HUMA) Stock Drops Despite Market Gains: Important Facts to Note
Humacyte, Inc. (HUMA) shares fell by 6.5% to $0.40, underperforming the broader market which saw the S&P 500 gain 0.41%. The company's stock has declined 26.74% over the last month, lagging behind the Medical sector. Analysts anticipate Humacyte to report an EPS of -$0.09 and revenue of $0.86 million in its upcoming earnings report, with a Zacks Rank of #3 (Hold).
Analysts Offer Insights on Healthcare Companies: Humacyte (HUMA) and Healthequity (HQY)
Analysts have issued bullish sentiments for Humacyte (HUMA) and Healthequity (HQY), two healthcare companies. H.C. Wainwright reiterated a Buy rating for Humacyte with a $4.00 price target, while Bank of America Securities maintained a Buy rating for Healthequity with a $125.00 price target. Both companies received favorable analyst consensus ratings.
H.C. Wainwright Maintains Humacyte(HUMA.US) With Buy Rating, Maintains Target Price $4
H.C. Wainwright has reiterated its Buy rating for Humacyte (HUMA.US) and maintained its price target at $4. This indicates continued confidence from the analyst firm in the company's prospects.
Humacyte stock price target reiterated at $1 by StoneX on demand
StoneX has reiterated a "Speculative Buy" rating and a $1.00 price target for Humacyte (NASDAQ:HUMA), noting that the company is undervalued according to InvestingPro analysis, with a Fair Value of $0.57. This comes as Humacyte reported an increase in hospitals ordering its Symvess product, rising to 49 from 34 in the previous quarter, indicating successful marketing efforts. Despite impressive revenue growth, InvestingPro Tips highlight the stock's high volatility and the company's rapid cash burn.
Humacyte stock gains ordering hospitals, H.C. Wainwright reiterates Buy
H.C. Wainwright reiterated a Buy rating and a $4.00 price target for Humacyte Inc. after the company announced that 15 additional hospitals had ordered its Symvess product, increasing the cumulative number of ordering hospitals to 49. Despite the positive news, Humacyte's stock currently trades significantly below its 52-week high, and the company reported second-quarter revenue and EPS that missed analyst expectations, though BTIG also maintained a Buy rating citing pipeline progress.
Humacyte stock price target reiterated at $1 by StoneX on demand
StoneX has reiterated a Speculative Buy rating and a $1.00 price target for Humacyte (NASDAQ:HUMA), noting the stock is currently undervalued according to InvestingPro analysis, with a fair value of $0.57. This reiteration comes as Humacyte reported an increase in hospitals ordering its Symvess product, rising from 34 to 49 by the end of the third quarter, indicating success in its marketing efforts. Despite the positive sales trend and 159% revenue growth, the company faces challenges with high stock volatility and rapid cash burn, as highlighted by InvestingPro Tips.
Humacyte reports 44% jump in hospitals ordering Symvess in Q3
Humacyte Inc. reported a significant increase in hospitals ordering its FDA-approved vascular trauma product, Symvess, in the third quarter of 2026. The number of hospitals rose by 44% to 49, with commercial sales accelerating each month. Symvess, approved by the FDA in December 2024, is used for extremity arterial injury to prevent limb loss, and Humacyte is on track to potentially exceed its year-end goal for new hospital additions.
49 hospitals ordered a bioengineered blood vessel. Several surgeons submitted patient case studies for presentations.
Humacyte (HUMA) reported a 44% increase in hospitals ordering Symvess, its FDA-approved bioengineered blood vessel for vascular trauma, rising from 34 to 49 hospitals in the third quarter of 2026. This growth positions the company to potentially surpass its year-end goal of adding 20 new hospitals. Humacyte plans to provide further commercial updates during its Q3 earnings call, highlighting growing surgeon interest and clinical utilization.
Humacyte Provides Commercial Update and Highlights Rapid Acceleration of Symvess Adoption by Hospitals
Humacyte, Inc. (Nasdaq: HUMA) announced a significant increase in the adoption of its FDA-approved Symvess product, an acellular tissue engineered vessel for vascular trauma. The number of hospitals ordering Symvess grew by 44% in Q3 2026, from 34 to 49, with strong commercial sales momentum and growing interest from vascular surgeons. The company anticipates substantial growth for the remainder of 2026, driven by its new commercial strategy.
Humacyte reports 44% rise in Symvess hospital orders in Q3
Humacyte (HUMA) reported a significant increase in hospital orders for its Symvess vascular graft, with a 44% rise during Q3 2026, reaching 49 hospitals. This growth surpassed the company's year-end goal of adding 20 new hospitals, reflecting the success of its commercial strategy. Symvess is an FDA-approved acellular tissue engineered vessel used for extremity arterial injury, though it carries a boxed warning for graft failure.
Humacyte to Present Phase 3 Dialysis Access Trial Results at ASN Kidney Week
Humacyte (HUMA) announced that interim results from its Phase 3 V012 trial will be presented at ASN Kidney Week. The article notes that a premium subscription is required to read the full details of this announcement from MT Newswires.
Humacyte’s phase 3 dialysis access trial results to be presented
Humacyte Inc. announced that interim results from its V012 Phase 3 clinical trial will be presented at the American Society of Nephrology Kidney Week 2026 on October 22. The trial compares Humacyte’s acellular tissue engineered vessel with autogenous arteriovenous fistula for hemodialysis access in female patients with end-stage kidney disease. The company plans to submit a supplemental Biologics License Application to the FDA this quarter to expand the Symvess label for hemodialysis access, supported by results from V012 and two prior Phase 3 trials.
Humacyte’s phase 3 dialysis access trial results to be presented By Investing.com
Humacyte Inc. (NASDAQ:HUMA) announced that interim results from its V012 Phase 3 clinical trial for hemodialysis access in female patients with end-stage kidney disease will be presented at the American Society of Nephrology Kidney Week 2026 on October 22. The company plans to submit a supplemental Biologics License Application to the FDA this quarter to expand the Symvess label for arteriovenous access for hemodialysis, supported by V012 and two other Phase 3 trials. Humacyte's acellular tissue engineered vessel has already received FDA approval for extremity vascular trauma and holds Regenerative Medicine Advanced Therapy and Fast Track designations for hemodialysis access.
A trial compares two blood-vessel options for women on dialysis. Interim results will be presented Oct. 22.
Humacyte (HUMA) will present interim Phase 3 V012 trial results comparing its bioengineered blood vessel (ATEV) with an arteriovenous fistula for hemodialysis access in women at the ASN Kidney Week on October 22, 2026. These results, along with two prior Phase 3 trials, will support a planned supplemental FDA application this quarter to expand the Symvess label for hemodialysis access. The company highlights the potential of ATEV to offer a better option for women who are more prone to fistula failure.
Form 4 Humacyte Inc For: 10 October By Investing.com
This article reports on a Form 4 filing for Humacyte Inc. on October 10th. It briefly mentions the company's stock symbol HUMA and its performance (-9.39%) at the time of publication. The content primarily serves as a placeholder for the filing information.
Form 4 Humacyte Inc For: 10 October By Investing.com
This article from Investing.com is a regulatory filing update, specifically a Form 4 for Humacyte Inc. dated October 10. It briefly mentions the company's stock symbol (HUMA) and its current performance (-9.39%), indicating an insider transaction or change in ownership that companies are required to disclose. The rest of the content includes market data, news headlines, and navigational links common to the Investing.com platform.
Humacyte (HUMA) Stock Fair Value Moves Lower After Analyst Target Cuts
Humacyte's (HUMA) stock fair value has decreased from US$2.05 to US$1.63 per share following updated analyst targets, with one analyst setting a US$0.50 target and another cutting to US$1. These adjustments reflect revised 2026 revenue expectations and an Equal Weight rating, indicating a more balanced outlook with increased execution risk. The changes align with new financial modeling that shows a very large revenue growth assumption but a significantly lower future P/E ratio.